Emerging Therapies for Genetic Cardiomyopathy: Hope for the Future

If you or a loved one has been diagnosed with a genetic form of heart disease, you may have heard the term cardiomyopathy. Cardiomyopathy is a disease of the heart muscle. In some people, the heart muscle becomes thickened (making it harder for the heart to fill and pump blood). In others, the heart muscle becomes enlarged or stretched, which can weaken the pumping. Some forms can also affect the way the heart’s electrical system works, leading to abnormal rhythms.

Cardiomyopathy can range from mild to serious. Symptoms can include shortness of breath, chest pain, swelling in the legs, a racing heart, or feeling faint. In many cases, cardiomyopathy runs in families due to a change (genetic variant) in a specific gene, this is called genetic cardiomyopathy.

Current Treatments for Cardiomyopathy

Today, treatments for cardiomyopathy focus on managing symptoms and preventing complications. These can include:

• Lifestyle and monitoring: Exercise, activities to avoid, pregnancy management, and more—plus regular heart imaging and rhythm checks to monitor changes over time.
• Medications: Drugs such as beta-blockers, blood thinners, or heart failure medications can help the heart pump and blood flow more effectively, control symptoms, and reduce the risk of dangerous rhythms or blood clots.
• Devices and procedures: Pacemakers help control abnormal electrical signals in the heart by sending small pulses. Implantable cardioverter-defibrillators (ICDs) also track the heart’s rhythm and can correct dangerous rhythms and prevent sudden cardiac death. Patients with obstructive hypertrophic cardiomyopathy (HCM) may need surgery to remove part of the thickened heart muscle. Some people also may be good candidates for a heart transplant.

While these options can help people live longer and feel better, they do not address the underlying genetic cause of the disease. That’s where new research offers hope.

The Promise of New Gene Therapies To Treat Genetic Cardiomyopathy

In the early 2020’s the first clinical trials of gene therapies for cardiomyopathy began—a milestone for patients and families affected by these conditions. Now there are several clinical trials underway with more expected to open soon.

Unlike current treatments, which focus on symptoms, gene therapies aim to address the root genetic problem. This could mean:

• Slowing or stopping disease progression before the heart becomes severely damaged.
• Reducing or preventing symptoms altogether.
• Potentially reversing harmful changes in the heart muscle.
• Decreasing the need for certain medications, procedures, or devices in the future.

This shift from symptom management to disease modification could be a game-changer. Instead of working around a faulty gene, these therapies are designed to repair, replace, or silence it—offering the possibility of lasting benefit.

Types of Gene Therapies in Development

Researchers are exploring several new approaches to treat genetic cardiomyopathies:

• Gene Replacement: A working copy of the gene is delivered into heart muscle cells. This can restore normal protein production and help the heart function better. For example, some experimental therapies aim to replace the missing MYBPC3 protein in certain forms of hypertrophic cardiomyopathy. There are multiple active trials for gene replacement therapies for several different genetic cardiomyopathies.
• Gene Editing: Using tools like CRISPR, scientists can repair or remove the variant (gene change) from the gene itself. This is being tested for ATTR-related cardiomyopathy. While still early in development for heart disease, it’s shown promise in laboratory and animal models, and could one day allow for precise, permanent fixes to disease-causing variants.
• Gene Silencing: This approach “turns off” the gene with the change (or variant). This is being tested for cardiac amyloidosis. Strategies like antisense oligonucleotides (ASOs) or RNA interference (RNAi) are already in use for other genetic diseases and could be adapted for cardiomyopathy.

In addition to gene therapies, there are also small-molecule treatments available and more being studied. These medicines do not change the gene itself but instead act on the affected protein or heart tissue, offering a more precise way to treat the problems caused by the gene change. For example, cardiac myosin inhibitors are a type of small molecule drug already approved for some people with hypertrophic cardiomyopathy, which help the heart muscle relax and pump more effectively.

Genetic Testing is The First Step to Access Gene Therapies

Because these therapies are designed for people with genetic changes in specific genes, the first step to accessing a current or future gene therapy is cardiomyopathy genetic testing. Testing can confirm the type of cardiomyopathy you have and the exact gene involved—information that’s essential for determining whether you may qualify for a clinical trial or future treatment.

These are examples of genes that we know play a role in different forms of cardiomyopathy:

• Hypertrophic cardiomyopathy (HCM): MYBPC3, MYH7, TNNT2, TNNI3, TPM1, ACTC1
• Dilated cardiomyopathy (DCM): TTN, BAG3, TNNT2
• Arrhythmogenic cardiomyopathy (ACM): PKP2, DSP, DSC2, JUP, TMEM43, LMNA, DSP, RBM20, SCN5A
• Restrictive cardiomyopathy (RCM): TNNI3, TNNT2, MYH7, DES, FLNC

At Genome Medical, our genetic counselors have deep expertise in cardiovascular genetics. In a genetic counseling appointment, they review your medical and family history to assess genetic risk, guide you through the testing process, and explain what your results mean for your health and your family. If you haven’t yet had genetic testing but would like to, or have questions about the genetic testing you’ve previously had, you can schedule a phone appointment with us. We also offer genetic counseling and testing for family members who may be at risk to have inherited cardiovascular disease.

Finding and Enrolling in Gene Therapy Clinical Trials

Once you know your genetic results, you can search for trials using resources like ClinicalTrials.gov or through specialty heart centers and academic medical institutions. You can search by condition name (for example, “hypertrophic cardiomyopathy” or “arrhythmogenic cardiomyopathy”) or by your specific gene (for example, “MYBPC3” or “PKP2”). Each trial listing will explain who can join, where the study is located, and how to contact the research team.

Deciding to join a clinical trial is an important decision. The benefits may include getting early access to new treatments, receiving enhanced medical care, and helping advance research that could benefit others. The risks may include side effects or the chance that the treatment does not work as expected. It’s important to weigh both the pros and cons so you can make the choice that’s right for you.

Your doctor or a genetic counselor can also help you decide if a trial might be a good fit and guide you to the next steps in the enrollment process.

At Genome Medical, our patients can receive notifications about relevant clinical trials. It’s one of the most rewarding parts of our work—connecting patients with potential life-changing treatments.

Looking Ahead

The future for people with genetic cardiomyopathy is brighter than ever. Gene-based therapies may transform care from symptom management to treating the root cause, offering hope for healthier, longer lives.

At Genome Medical, we’ll continue to keep you updated on new developments and help you and your family access the best possible care—today and in the years to come.